New CEO to Strengthen Moberg Derma’s Organization

The Swedish pharmaceutical company, Moberg Derma, which focuses on skin diseases, today announced that it is strengthening its organization by appointing Tommy Nilsson as the new CEO. Peter Wolpert, Moberg Derma’s current CEO and one of the company’s founders, will stay on as working Vice Chairman of the Board, focusing on international partnerships and investor relations.

”We are continuously working on strengthening our organization to enable further expansion. Tommy Nilsson is a very valuable addition as our new CEO,” says Peter Wolpert. ”Tommy’s solid background as head of a Nordic marketing company within dermatology and 20 years within the pharmaceuticals industry is an excellent complement to the experience that we already have within the company. I am looking forward to a fruitful collaboration as we continue to develop Moberg Derma.”

Before joining Moberg Derma, Tommy Nilsson held the position as CEO of Galderma Nordic. His previous experience includes responsibility for a business area at Orion Pharma and more than ten years within Astra. Tommy Nilsson has a research background within neuropharmacology and an Executive MBA.

“I’m very impressed by what I have seen of Moberg Derma so far. It’s fantastic that the company already has products in clinical phase III studies, and equally impressive how much has been achieved since the company was formed in March 2006,” says Tommy Nilsson. ”I look forward to leading Moberg Derma in the exciting times that are ahead of us. The company has great potential and we will work hard to make sure that it will be fully exploited.”

Contact:
Peter Wolpert, Vice Chairman & Co-founder
Telephone: +46 (0)8 522 307 00
Cellphone: +46 (0)70 735 71 35
e-mail: peter.wolpert@mobergderma.se

Tommy Nilsson, CEO
Telephone: +46 (0)8 522 307 00
Cellphone: +46 (0)70 870 47 21
e-mail: tommy.nilsson@mobergderma.se

For more information, please visit our website www.mobergderma.se